Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose IL-2 in Early Alzheimer's Disease
2024-516565-36-00Phase 2Authorised
- Sponsor
- GHU Paris psychiatrie & neurosciences
- Start
- Nov 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of aldesleukin in Alzheimer's disease (AD), sponsored by GHU Paris psychiatrie & neurosciences. Planned start Nov 2024; status: authorised.
02
Drugs
aldesleukin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-516565-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516565-36-00.